Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Talazoparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2021
Lead Product(s) : Talazoparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Talazoparib Tosylate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : BioMarin Pharmaceutical | Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2015
Lead Product(s) : Talazoparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : BioMarin Pharmaceutical | Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable